Related Experiment Video
Updated: May 2, 2026
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Arterial hypertension during treatment with triptorelin in a child with Williams-Beuren syndrome
Ekaterini Siomou1, Chrysoula Kosmeri, Maria Pavlou
1Departments of Pediatrics, University Hospital of Ioannina, Stavros Niarchos Avenue, 45 500, Ioannina, Greece, eksiomou@yahoo.gr.
Insights
Severe arterial hypertension (AHT) developed in a child with Williams-Beuren syndrome (WBS) during triptorelin treatment. Blood pressure normalized after discontinuing the gonadotropin-releasing hormone analog, suggesting a rare drug-induced effect.
Area of Science:
- Pediatric Endocrinology
- Cardiology
- Pharmacology
Background:
- Arterial hypertension (AHT) is frequently observed in children with Williams-Beuren syndrome (WBS).
- The precise causes of AHT in WBS are not fully understood, with many cases considered idiopathic.
- Cardiovascular and renal abnormalities contribute to AHT in some WBS patients.
Observation:
- A 10-year-old girl with WBS experienced severe AHT while undergoing treatment with triptorelin.
- Triptorelin, a long-acting gonadotropin-releasing hormone (GnRH) analog, was administered for precocious puberty.
- Diagnostic evaluations excluded other known causes of AHT in WBS.
Findings:
- Discontinuation of triptorelin led to the normalization of the patient's blood pressure.
- Long-term follow-up confirmed sustained normotension without antihypertensive medication.
- This is the first reported instance of AHT linked to triptorelin in a child with WBS.
Implications:
- Clinicians should consider the potential for triptorelin-induced AHT in pediatric patients.
- Children with Williams-Beuren syndrome may be at increased risk for this rare adverse effect.
- Awareness of this association is crucial for monitoring and managing AHT in susceptible children.
Background:
Arterial hypertension (AHT) is a common finding in children with Williams-Beuren syndrome (WBS). Although cardiovascular and renal abnormalities can explain the AHT in some patients with WBS, its etiology is not fully understood and most cases are considered idiopathic.
Case-Diagnosis/Treatment:
The case is reported of a 10-year-old girl with WBS who developed severe AHT during treatment with triptorelin, a long-lasting gonadotropin-releasing hormone (GnRH) analog, administered because of early normal puberty. Comprehensive diagnostic studies ruled out other known causes of AHT associated with WBS. After discontinuation of triptorelin, the blood pressure remained within the normal range for her age and height with no antihypertensive treatment on long-term follow-up. To the best of the authors' knowledge, this is the first report of AHT associated with triptorelin administration in a child with WBS.
Conclusions:
Clinicians should be aware of the possibility, although rare, of AHT developing during triptorelin administration in childhood, specifically in patients at increased risk of AHT, such as those with WBS.
More Related Videos
04:37Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
05:31Murine Model of Thoracic Aortic Dissection Induced by Oral β-Aminopropionitrile and Subcutaneous Angiotensin II Infusion
Published on: May 16, 2025
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies